文献速递脊柱脊髓外科神经重症

退行性颈髓病免疫机制的系统综述

Characterizing immune involvement in degenerative cervical myelopathy: a systematic review.
PubMed 文献 · J Neurosurg Spine · 2026-05-01

该系统性综述检索PubMed至2024年8月1日,最终纳入10项研究,评估免疫反应在退行性颈髓病(DCM)中的作用。发现DCM患者脑脊液促炎细胞因子升高、血脊髓屏障破坏及组织凋亡与自噬异常,外周免疫谱向M2巨噬细胞和活化CD4 T细胞偏移,部分生物标志物与术后临床改善相关。

要点

  • DCM存在免疫炎症成分参与神经退行性变。
  • 脑脊液IL-8、TNF-α升高及寡克隆IgG带增多。
  • 术后S100b及围术期CSF神经丝轻链、GFAP与疗效相关。

核心结论

  • 免疫反应与DCM疾病进展显著交互,炎症机制可影响临床结局与治疗疗效。
  • 需进一步研究DCM免疫成分,为手术减压联合靶向免疫治疗提供依据。

研究设计与样本

  • 遵循PRISMA指南的系统性文献综述,检索PubMed数据库至2024年8月1日。
  • 纳入报告DCM免疫 involvement 的分子、组织学、脑脊液或外周标志物的研究,排除系统综述、病例报告及动物研究。
  • 由两名盲法作者筛选文献,最终从113项研究中纳入10项。

主要发现

  • DCM患者脑脊液促炎细胞因子升高,包括白介素-8和肿瘤坏死因子-α。
  • DCM患者脑脊液寡克隆IgG带增加及血脊髓屏障破坏。
  • DCM组织显示Fas介导通路凋亡、自噬受损及活化髓系细胞染色增加(与对照相比)。
  • 外周免疫谱显示DCM患者M2巨噬细胞和活化CD4 T细胞增加。
  • 血清S100b术后值及围术期脑脊液神经丝轻链和胶质纤维酸性蛋白水平与治疗后临床改善和良好结局显著相关。

临床怎么用

  • 关注DCM患者脑脊液及外周免疫炎症标志物,辅助评估疾病严重度与治疗反应。
  • 术后血清S100b及围术期脑脊液神经丝轻链、GFAP可能作为预后参考指标。
  • 手术减压仍是基础,免疫靶向治疗为未来潜在辅助方向。

局限性

  • 符合纳入标准的研究数量有限。
  • 存在因果解释偏倚和时间偏倚。
  • 缺乏标准化的跨研究生物标志物分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Degenerative cervical myelopathy (DCM) is the most common cause of cervical spinal cord impairment in adults. It is described as progressive, age-related spinal cord compression due to degenerative changes in the spinal column. While the mechanical pathology of DCM is well characterized, the immune system's role in the disease's neurological progression and potential as a therapeutic target remains unclear. The authors aimed to comprehensively review the available literature on immunological involvement in DCM pathogenesis. Understanding the interactions between inflammation, apoptosis, and neurodegeneration in DCM may provide insights into novel treatment strategies. METHODS: A systematic literature review was conducted in the PubMed database through August 1, 2024, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Papers met inclusion criteria for the review if they reported on molecular, histological, CSF, or peripheral markers of immune involvement or the immune response, causation, or relation to DCM. Systematic reviews, case reports, or animal studies were excluded. Studies were screened by two blinded authors based on relevance and synthesized to assess the immune environment in DCM. RESULTS: A total of 113 studies were identified, with 10 meeting the inclusion criteria. Findings revealed elevated proinflammatory cytokines in the CSF of DCM patients, including interleukin-8 and tumor necrosis factor-α, as well as increased oligoclonal IgG bands and blood-spinal cord barrier disruption. Histological analysis demonstrated apoptosis via Fas-mediated pathways, impaired autophagy, and increased staining for activated myeloid cells in DCM tissue compared to controls. Peripheral immune profiling indicated increased M2 macrophages and activated CD4 T cells in DCM patients. Furthermore, serum S100b postoperative values and perioperative CSF levels of neurofilament light chain and glial fibrillary acidic protein correlated significantly with clinical improvement and favorable outcomes following treatment. This review is limited by the number of eligible studies, causal interpretation and temporal bias, and lack of standardized interstudy biomarker analysis. These findings identify an immune component of DCM neurodegeneration that may influence disease severity and treatment response. CONCLUSIONS: There is a significant interplay between immune responses and DCM disease progression, revealing how inflammatory mechanisms can influence clinical outcomes and treatment efficacy. Further studies are warranted to understand the immune component of DCM and pave the way for targeted immunotherapies alongside surgical decompression.

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Chabot PJ, Winans NJ, Fuller JS, et al. Characterizing immune involvement in degenerative cervical myelopathy: a systematic review. J Neurosurg Spine. 2026. PMID: 42066366. doi:10.3171/2025.12.SPINE251122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。